WO2023126867 - SELF-ADMINISTRATION INJECTION DEVICE FOR RISPERIDONE
National phase entry:
Publication Number
WO/2023/126867
Publication Date
06.07.2023
International Application No.
PCT/IB2022/062868
International Filing Date
29.12.2022
Title **
[English]
SELF-ADMINISTRATION INJECTION DEVICE FOR RISPERIDONE
[French]
DISPOSITIF POUR L'INJECTION DE RISPÉRIDONE EN AUTO-ADMINISTRATION
Applicants **
ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED
Inventors
VALLABHBHAI, Patel Bhaveshkumar
KINI, Rajesh
MOHAN, Vignesh
Priority Data
202141062125
31.12.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1956 | |
| EPO | Filing, Examination, Granting | 11558 | |
| Japan | Filing, Examination, Granting | 1998 | |
| South Korea | Filing, Examination, Granting | 1804 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,056
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to an self-administration injection device, comprising drug reservoir of long-acting risperidone microspheres in non-aqueous liquid vehicle. The risperidone microspheres are suspended in non-aqueous liquid vehicle such as triglycerides. The self-administration injection device is auto-injector for single dose.[French]
La présente invention concerne un dispositif d'injection en auto-administration, comprenant un réservoir à médicament contenant des microsphères de rispéridone à action prolongée dans un véhicule liquide non aqueux. Les microsphères de rispéridone sont mises en suspension dans un véhicule liquide non aqueux tel que des triglycérides. Le dispositif d'injection en auto-administration est un auto-injecteur unidose.